Answer
The most frequently reported adverse reaction to nirsevimab in clinical trials was rash (0.7%), occurring within 14 days after dosing and usually mild to moderate in intensity.
Sources for this answer
- Beyfortus 100 mg solution for injection in pre filled syringeSANOFI · emc · SmPC §4.8 Undesirable effects · Version 3Document updated
Sources checked